GREEN preferred SGLT2i. Also indicated for use as per NICE TA288, NICE TA390 and NICE TA418 for type 2 diabetes: in combination (triple therapy) with other glucose-lowering agents and for use as monotherapy. See local type 2 diabetes guidance. (Decision date Dec 2022)
Type 2 Diabetes with CKD:
GREEN - as per NICE NG28, and NG203 for adults with CKD and type 2 diabetes, in additions to an ACEI or ARB at an optimised dose. (Decision date - Sep 2021, updated Dec 2021).
Chronic Heart failure:
GREEN after specialist/consultant initiation and stabilisation: NICE TA679 - Dapagliflozin for treating chronic heart failure with
reduced ejection fraction. Dapagliflozin to be initiated and stabilised by specialist/consultant before transferring the patient to primary care. See local heart failure guidance for further details. (Decision date - April 2021).
GREEN after specialist/consultant recommendation:NICE TA902 - Dapagliflozin for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults. (Decision date - November 2023)
Chronic Kidney Disease:
GREEN: NICE TA775 - Dapagliflozin for treating chronic kidney disease. (Decision date - April 2022, April 2023).
Type 1 diabetes:
RED: Dapagliflozin with insulin for treating type 1 diabetes (unlicenced).
NICE have withdrawn guidance for this indication, because dapagliflozin with insulin is no longer licenced for treating type 1 diabetes. (November 2021).
